<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is classified into 3 clinical subsets: endemic, <z:hpo ids='HP_0003745'>sporadic</z:hpo>, and <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo>-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>So far, possible differences in their gene expression profiles (GEPs) have not been investigated </plain></SENT>
<SENT sid="2" pm="."><plain>We studied GEPs of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> subtypes, other B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and B lymphocytes; first, we found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is a unique <z:chebi fb="0" ids="23367">molecular entity</z:chebi>, distinct from other B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Indeed, by unsupervised analysis <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> clearly clustered apart of other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Second, we found that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> subtypes presented slight differences in GEPs </plain></SENT>
<SENT sid="5" pm="."><plain>Particularly, they differed for genes involved in cell cycle control, B-cell receptor signaling, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor/nuclear factor ÎºB pathways </plain></SENT>
<SENT sid="6" pm="."><plain>Notably, by reverse engineering, we found that endemic and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> diverged for genes dependent on RBL2 activity </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, we found that <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> were intimately related to germinal center cells, differing from them for molecules involved in cell proliferation, immune response, and signal transduction </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, to validate GEP, we applied immunohistochemistry to a large panel of cases and showed that RBL2 can cooperate with MYC in inducing a neoplastic phenotype in vitro and in vivo </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, our study provided substantial insights on the pathobiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e>, by offering novel evidences that may be relevant for its classification and possibly future treatment </plain></SENT>
</text></document>